All In Biotech

Drug Trial Radar · NCT03000257

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

182

Actual

Start

Dec 14, 2016

Primary completion

Mar 29, 2022

Study completion Mar 29, 2022

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.

Conditions

  • Advanced Solid Tumors

Interventions

  • VenetoclaxDrug

    Tablet taken orally

  • Rovalpituzumab TesirineDrug

    Intravenous infusion

  • ABBV-181Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Recommended Phase 2 Dose (RPTD) for BudigalimabTime frame: Up to 6 months
  2. Part 1: Maximum tolerated dose (MTD) of BudigalimabTime frame: Up to 6 months
  3. Part 1 and Part 3: Terminal Half-life (t1/2) of BudigalimabTime frame: Up to 4 Weeks
  4. Part 1 and Part 3: Maximum Observed Serum Concentration (Cmax) of BudigalimabTime frame: Up to 12 Weeks
  5. Part 1 and Part 3: Time to Cmax (Tmax) of BudigalimabTime frame: Up to 12 Weeks
  6. Part 1 and Part 3: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of BudigalimabTime frame: Up to 12 Weeks
  7. Part 2: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Rovalpituzumab Tesirine CombinationTime frame: Up to 6 Months
  8. Part 3: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Venetoclax Combination.Time frame: Up to 6 Months
  9. Part 3: Maximum Observed Serum Concentration (Cmax) for VenetoclaxTime frame: Up to 12 Weeks
  10. Part 3: Area Under the Serum Concentration Time Curve from Time 0 to 24 Hours Post-dose (AUC(0-24)) of VenetoclaxTime frame: Up to 12 Weeks
  11. Part 3: Time to Cmax (Tmax) of VenetoclaxTime frame: Up to 12 Weeks
  12. Part 1, Part 2, Part 3: Number of Participants with Adverse EventsTime frame: From first dose of study drug until 90 days following last dose of study drug (up to 24 months)

Locations

26 sites in 10 countries. Site status is shown where the registry gives one.

  • Moores Cancer Center at UC San Diego /ID# 157374

    La Jolla, California

  • The University of Chicago Medical Center /ID# 157375

    Chicago, Illinois

  • Carolina BioOncology Institute /ID# 157376

    Huntersville, North Carolina

  • South Texas Accelerated Research Therapeutics /ID# 157378

    San Antonio, Texas

  • Virginia Cancer Specialists - Fairfax /ID# 157377

    Fairfax, Virginia

  • Blacktown Hospital /ID# 167386

    Blacktown, New South Wales, Australia

  • St Vincent's Hospital Melbourne /ID# 167552

    Fitzroy Melbourne, Victoria, Australia

  • Linear Clinical Research /ID# 170797

    Nedlands, Western Australia, Australia

  • Medizinische Universitaet Graz /ID# 168752

    Graz, Styria, Austria

  • Universitair Ziekenhuis Antwerpen /ID# 170702

    Edegem, Antwerpen, Belgium

  • UZ Gent /ID# 170881

    Ghent, Oost-Vlaanderen, Belgium

  • Cross Cancer Institute /ID# 167603

    Edmonton, Alberta, Canada

  • Docrates Cancer Center /ID# 166838

    Helsinki, Finland

  • Tampere University Hospital /ID# 166839

    Tampere, Pirkanmaa, Finland

  • Institut Bergonie /ID# 162662

    Bordeaux, Gironde, France

  • Institut du Cancer de Montpellier - Val d'Aurelle /ID# 163999

    Montpellier, Herault, France

  • Centre Leon Berard /ID# 162660

    Lyon, Rhone, France

  • Institut Gustave Roussy /ID# 162753

    Villejuif, Val-de-Marne, France

  • National Cancer Center Hospital East /ID# 166433

    Kashiwa-shi, Chiba, Japan

  • National Hospital Organization Kyushu Cancer Center /ID# 206229

    Fukuoka, Fukuoka, Japan

  • National Cancer Center Hospital /ID# 166279

    Chuo-ku, Tokyo, Japan

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 163862

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro /ID# 163861

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia /ID# 163925

    Valencia, Spain

  • National Taiwan University Hospital /ID# 163997

    Taipei, Taiwan

  • Taipei Medical University Hospital /ID# 163998

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.